(Q24236037)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

0 references

1 reference

title

Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

chronic obstructive pulmonary disease

14 February 2020

main subject

0 references

author

Christopher Cates

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Sally Spencer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

David J Evans

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Charlotta Karner

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

language of work or name

English

0 references

publication date

5 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

CD007033

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Relationship between respiratory symptoms and medical treatment in exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

The TORCH (towards a revolution in COPD health) survival study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Budesonide/formoterol: in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Safety of long-acting beta-agonists in stable COPD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Time course of recovery of health status following an infective exacerbation of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

Cardiovascular events in patients with COPD: TORCH study results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

Quality of life changes in COPD patients treated with salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

Health Status Deterioration in Patients with Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

Methods for therapeutic trials in COPD: lessons from the TORCH trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

10.1002/14651858.CD007033.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2275723

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

OpenCitations bibliographic resource ID

14 February 2020

2275723

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference